These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26628299)

  • 1. Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
    Liu W; Ning J; Li C; Hu J; Meng Q; Lu H; Cai L
    Tumour Biol; 2016 May; 37(5):6331-6. PubMed ID: 26628299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
    Yang J; Yang C; Zhang S; Mei Z; Shi M; Sun S; Shi L; Wang Z; Wang Y; Li Z; Xie C
    Cancer Biol Ther; 2015; 16(8):1194-204. PubMed ID: 26054751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Gremlin promotes non-small cell lung cancer progression.
    Yin Y; Yang Y; Yang L; Yang Y; Li C; Liu X; Qu Y
    Tumour Biol; 2016 Feb; 37(2):2597-602. PubMed ID: 26392110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
    Li B; Yao Z; Wan Y; Lin D
    Oncotarget; 2016 Nov; 7(47):77342-77347. PubMed ID: 27816965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
    Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
    Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
    Shen H; Zhu F; Liu J; Xu T; Pei D; Wang R; Qian Y; Li Q; Wang L; Shi Z; Zheng J; Chen Q; Jiang B; Shu Y
    PLoS One; 2014; 9(7):e103305. PubMed ID: 25058005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells.
    Jia Z; Zhang Y; Yan A; Wang M; Han Q; Wang K; Wang J; Qiao C; Pan Z; Chen C; Hu D; Ding X
    Cell Death Dis; 2020 Aug; 11(8):670. PubMed ID: 32820157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells.
    Schnitzer SE; Weigert A; Zhou J; Brüne B
    Mol Cancer Res; 2009 Mar; 7(3):393-401. PubMed ID: 19240180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
    Nishimura Y; Takiguchi S; Yoshioka K; Nakabeppu Y; Itoh K
    Int J Oncol; 2012 Oct; 41(4):1520-30. PubMed ID: 22859339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
    Cui F; Wang W; Wu D; He X; Wu J; Wang M
    Clin Transl Oncol; 2016 Jul; 18(7):722-7. PubMed ID: 26474873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
    Emdad L; Lebedeva IV; Su ZZ; Gupta P; Sarkar D; Settleman J; Fisher PB
    J Cell Physiol; 2007 Feb; 210(2):549-59. PubMed ID: 17111370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
    Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
    Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol suppresses NSCLC cell growth, invasion and migration by mediating Wnt/β-catenin pathway via downregulating SIX4 and SPHK2.
    Wang X; Liu C; Wang J; Tian Z
    J Chemother; 2024 Sep; 36(5):411-421. PubMed ID: 37968995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo.
    Dai L; Smith CD; Foroozesh M; Miele L; Qin Z
    Int J Cancer; 2018 May; 142(10):2153-2162. PubMed ID: 29277894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
    Li Z; Zhou S; Zhang L; Su C; Hang J; Zhao Y; Su B; Zhou C
    Med Oncol; 2011 Jun; 28(2):572-7. PubMed ID: 20237869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
    Yamamoto C; Basaki Y; Kawahara A; Nakashima K; Kage M; Izumi H; Kohno K; Uramoto H; Yasumoto K; Kuwano M; Ono M
    Cancer Res; 2010 Nov; 70(21):8715-25. PubMed ID: 20959484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
    Tsai CM; Chen JT; Chiu CH; Lai CL; Hsiao SY; Chang KT
    Lung Cancer; 2013 Nov; 82(2):305-12. PubMed ID: 24055492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.